S84.F SCOPE FLUIDICS SA ZY-10
- Market cap
- EUR 101M
- P/E
- -
- P/B
- 2.92x
- ROE
- -34.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is S84.F undervalued?
Graham numberThe Graham number of SCOPE FLUIDICS SA ZY-10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SCOPE FLUIDICS SA ZY-10 fundamental analysis
No fundamental analysis for SCOPE FLUIDICS SA ZY-10 yet.
SCOPE FLUIDICS SA ZY-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SCOPE FLUIDICS SA ZY-10
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. It offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is headquartered in Warsaw, Poland.
Full company profileSCOPE FLUIDICS SA ZY-10 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SCOPE FLUIDICS SA ZY-10 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 404K | 516K | 131K | 100K | 118K |
| Gross Profit | -656K | -468K | -1.37M | -1.18M | -3.64M | -3.39M |
| Operating Income | -10.2M | -25.2M | -28.7M | -32.5M | -47.3M | -52.6M |
| EBITDA | - | 397M | -17.3M | 87.1M | -43.7M | -43.9M |
| Net Income | -16.6M | 318M | -18.8M | 65.4M | -46.4M | -47.2M |
| EPS | -6.19 | 117 | -6.89 | 24 | -15 | -15 |
| Balance Sheet | ||||||
| Total Assets | 52.7M | 346M | 101M | 173M | 196M | 171M |
| Total Liabilities | 46.0M | 13.2M | 20.6M | 26.5M | 33.5M | 32.0M |
| Shareholders' Equity | 6.74M | 333M | 80.9M | 146M | 162M | 139M |
| Cash & Short-term Investments | 18.1M | 332M | 66.3M | 129M | 93.2M | 53.6M |
| Cash Flow | ||||||
| Operating Cash Flow | -21.4M | -28.2M | -19.1M | -25.1M | -46.1M | -54.2M |
| Capital Expenditure | 4.91M | 1.30M | 2.15M | 6.56M | 13.4M | 24.3M |
| Free Cash Flow | -26.3M | -29.5M | -21.2M | -31.7M | -59.5M | -78.5M |
| Ratios | ||||||
| ROE | -246.9% | 95.7% | -23.2% | 44.7% | -28.5% | -34.0% |
| ROA | -31.5% | 92.0% | -18.5% | 37.8% | -23.7% | -27.6% |
| Net Profit Margin | - | 78,833.9% | -3,640.5% | 49,939.7% | -46,364.0% | -40,001.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SCOPE FLUIDICS SA ZY-10 dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Mar 24, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | PLN 233M | 86 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns SCOPE FLUIDICS SA ZY-10
- Insiders 22.85%
- Institutions 21.74%
- Public & others 55.42%
- Shares outstanding 3.17M
- Free float 2.34M
SCOPE FLUIDICS SA ZY-10 company profile
- Company name
- SCOPE FLUIDICS SA ZY-10
- Ticker
- S84.F
- ISIN
- PLSCPFL00018
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 175
- Fiscal year end
- December
- Address
- Ogrodowa 58 Street, Warsaw, Poland, 00-876
- Phone
- 48 22 376 2114
- Website
- scopefluidics.com
About SCOPE FLUIDICS SA ZY-10
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. It offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is headquartered in Warsaw, Poland.
SCOPE FLUIDICS SA ZY-10 management
3- Mr. Piotr GarsteckiChairman of the Management Board
- Mr. Marcin IzydorzakVice President of the Management Board
- Mr. Szymon Michal RutaVice-President of the Management Board & Financial Director